DEA Proposes Higher 2027 Psychedelic Production Quotas

The Drug Enforcement Administration filed a draft notice raising production limits for several Schedule I and II psychedelic substances.

Updated on Nov. 9, 2026 in Drug Crime

Bold flat-color editorial illustration of clear glass flasks of amber and blue liquid on a slate bench beneath a faceted crystal form, evoking psychedelic research production. — The Drug Enforcement Administration proposed higher 2027 production quotas for ibogaine, MDMA, psilocybin and psilocyn, citing clinical research and trials for PTSD and depression. AI Illustration. Upload story photo >

Live Poll

Should the U.S. government allow more legal production of psychedelics for medical research?

The Drug Enforcement Administration filed a draft Federal Register notice proposing increased 2027 annual production quotas for Schedule I and II psychedelic substances. The proposal would raise ibogaine, MDMA, psilocybin and psilocyn limits while holding marijuana production at 2026 levels.

Why it matters

The DEA said the MDMA and ibogaine increases support research and clinical trials for PTSD and depression. The proposal aligns with executive orders issued by President Trump, including one signed in April focused on psychedelics research and access.

The DEA proposes raising ibogaine production from 210 grams in 2026 to 12,002 grams in 2027 and MDMA from 12,000 to 33,296 grams. Separate Schedule III quotas have not yet been proposed, and DEA is still assessing data sources to estimate legitimate need for rescheduled marijuana.

The players

Drug Enforcement Administration

The federal agency responsible for enforcing the nation's controlled substances laws and setting annual production quotas for scheduled drugs.

Donald Trump

The current President of the United States, who signed executive orders in April 2026 focused on psychedelics research and access.

Todd Blanche

The U.S. Attorney General who signed the order moving medical marijuana to Schedule III earlier in 2026.

The details

The draft notice was filed Monday and will be formally published Wednesday in the Federal Register. Public comments will be accepted for 30 days, and DEA is registering manufacturers and distributors for substances moved to Schedule III, including state-licensed medical cannabis.

April 2026: Trump signed an executive order on psychedelics research and access.
Earlier in 2026: Attorney General Todd Blanche signed an order moving medical marijuana to Schedule III.
November 9, 2026: DEA filed the draft Federal Register notice on 2027 quotas.
November 11, 2026: The quota notice is scheduled for formal publication.
2027: Proposed psychedelic production quotas would take effect.

Legal Context

The proposal follows Trump's April 2026 executive order on psychedelics research and access and extends a broader federal shift toward rescheduling. It comes after the earlier move of medical marijuana to Schedule III, which DEA is now implementing through registration and quota actions.

Researchers and clinical programs studying MDMA, ibogaine and psilocybin could see greater legal access to these substances if the proposed quotas are finalized. Individuals outside licensed research will see no direct change to how these substances are obtained.

The takeaway

Proposed quota increases signal federal support for psychedelic research, but final numbers depend on public comment and DEA review. Readers should watch the November 11 Federal Register notice for the next concrete step.

What happens next

The Federal Register quota notice is scheduled for formal publication on November 11, 2026, and public comments will be accepted for 30 days after publication.